At a Glance:

The ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium was officially convened in July 2023 between the non-profit Health and Environmental Sciences Institute (HESI Global) and the Broad Institute of Harvard and MIT. The Consortium is supported by an award from the Massachusetts Life Sciences Center (MLSC), in synergy with partnered resources and expertise from industry partners and in-kind contributions from academic, government, NGO, and biotech partners.

This exciting effort engages >160 global experts in toxicology, cell biology, bioinformatics, risk assessment, and assay development from more from 17 academic institutes, 7 government agencies, 17 industry organizations, and 3 non-government organizations. 

Advancing Human-Relevant Safety Assessment Through Integrated Omics

The OASIS Consortium is advancing Next Generation Risk Assessment by integrating multi-omics technologies—including transcriptomics, proteomics, and high-content Cell Painting—across a spectrum of human-relevant biological models. With an initial focus on liver safety, OASIS combines molecular and phenotypic data with exposure context to improve translation from in vitro systems to in vivo and clinical outcomes. By leveraging compounds with well-characterized safety profiles, the consortium is building more predictive, efficient, and human-relevant approaches to chemical safety assessment, while supporting reduced reliance on animal testing and advancing regulatory science across sectors.

Study Overview